Suchergebnisse - "Idiopathic pulmonary arterial hypertension"

PubPharm (444)

41

Mapping of the lung megakaryocytes : A role in pathogenesis of idiopathic pulmonary arterial hypertension?

enthalten in: Pathology, research and practice | 2022

von Balko, J. | Havlin, J. | CasasMendez, F. | +5

42

Pulmonary arterial hypertension sensitive to calcium channel blocker, but not advanced pulmonary hypertension treatment : a case report

enthalten in: European heart journal. Case reports | 2022

von Hirakawa, K. | Aoki, T. | Tsuji, A. | +1

43

Double-blind, randomized, placebo-controlled, dose-finding, parallel-group study to assess the hemodynamic effects, clinical efficacy, tolerability and safety of Aviptadil (Vasoactive Intestinal Peptide) after single and repeated inhalation in patients with pulmonary arterial hypertension. : Double-blind, randomized, placebo-controlled, dose-finding, parallel-group study to assess the hemodynamic effects, clinical efficacy, tolerability and safety of Aviptadil (Vasoactive Intestinal Peptide) after single and repeated inhalation in patients with pulmonary arterial hypertension.

enthalten in: WHO International Clinical Trials Registry Platform | 2022

44

An open-label, long term extension study for treatment of pulmonary arterial hypertension in paediatric patients aged 8 years up to 18 years who have participated in AMB112529 and in whom continued treatment with ambrisentan is desired : An open-label, long term extension study for treatment of pulmonary arterial hypertension in paediatric patients aged 8 years up to 18 years who have participated in AMB112529 and in whom continued treatment with ambrisentan is desired

enthalten in: WHO International Clinical Trials Registry Platform | 2022

45

The effects of dapagliflozin in patients with elevated blood pressure in the lungs : Effects of DAPAgliflozin on cardiopulmonary exercise capacity and hemodynamics in Pulmonary Arterial Hypertension: A double blind randomized trial

enthalten in: WHO International Clinical Trials Registry Platform | 2022

46

Double-blind, randomized, placebo-controlled, dose-finding, parallel-group study to assess the hemodynamic effects, clinical efficacy, tolerability and safety of Aviptadil (Vasoactive Intestinal Peptide) after single and repeated inhalation in patients with pulmonary arterial hypertension. : Double-blind, randomized, placebo-controlled, dose-finding, parallel-group study to assess the hemodynamic effects, clinical efficacy, tolerability and safety of Aviptadil (Vasoactive Intestinal Peptide) after single and repeated inhalation in patients with pulmonary arterial hypertension.

enthalten in: WHO International Clinical Trials Registry Platform | 2022

47

An open-label, long term extension study for treatment of pulmonary arterial hypertension in paediatric patients aged 8 years up to 18 years who have participated in AMB112529 and in whom continued treatment with ambrisentan is desired : An open-label, long term extension study for treatment of pulmonary arterial hypertension in paediatric patients aged 8 years up to 18 years who have participated in AMB112529 and in whom continued treatment with ambrisentan is desired

enthalten in: WHO International Clinical Trials Registry Platform | 2022

48

The effects of dapagliflozin in patients with elevated blood pressure in the lungs : Effects of DAPAgliflozin on cardiopulmonary exercise capacity and hemodynamics in Pulmonary Arterial Hypertension: A double blind randomized trial

enthalten in: WHO International Clinical Trials Registry Platform | 2022

49

Cardiovocal Syndrome Associated With Idiopathic Pulmonary Arterial Hypertension : A Case Report and Literature Review

enthalten in: Cureus | 2022

von Ohi, K. | Suzuki, J. | Ikeda, R. | +2

50

Changes in the Characteristics and Initial Treatments of Pulmonary Hypertension Between 2008 and 2020 in Japan

enthalten in: JACC. Asia | 2022

von Tamura, Y. | Kumamaru, H. | Inami, T. | +10